Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Psychiatrists who Treat Anxiety Disorders (US)

November 24, 2008
Efficacy isn't everything
Analysis of: 2nd Generation Antidepressants Prove Effective (health.usnews.com)
This article tells you only that the drugs are equally effective, but not what that really means in real life.
Analysis of: St John's Wort 'as good as Prozac' (ukpress.google.com)
This "report" tells you nothing that you need to know in order to assess the validity of these studies.  We have always known that St. John's Wort has some effectiveness---but it certainly does not come without side-effects.  Where is the information about the length of the studies, the relative...
Analysis of: Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound (newsroom.lilly.com)
Gamma secretase inhibitors are one of several kinds of drugs being studied for the prevention/amelioration of Alzheimer's.  In concept they make sense.
July 31, 2008
Be very careful
Analysis of: Blood pressure drugs may protect against Alzheimer's (www.washingtonpost.com)
All is not as it seems when reported in the press, especially the non-scientific press.
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy (www.medicalnewstoday.com)
-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 
Analysis of: Doctors Say Medication Is Overused in Dementia (www.nytimes.com)
We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
Analysis of: Johnson & Johnson Presents Tapentadol Phase 3 Clinical Data at American Pain Society's Annual Meeting (www.investor.jnj.com)
Don't bother listening to the May 6 audio presentation, as it is a useless waste of time.  Just look at the pdf slide presentation, showing tapentadol IR to provide equivalent pain control to 10 or 15mg oxycodone, with reduced GI side effects, in treating acute bunionectomy pain and also arthritis...
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
NNR's are being heavily studied for several uses and are looking promising.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 121

Analytics


Generated at 2009-01-09T13:00:20.343